Trial Profile
NCRN086 - INDUSTRY STUDY.
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 13 Aug 2012
Price :
$35
*
At a glance
- Drugs Carlumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Centocor
- 31 Jul 2010 Status changed from not yet recruiting to suspended as reported by United Kingdom Clinical Research Network record.
- 02 Jul 2009 New trial record